AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Opus Genetics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SC04V7
3.47▼ 0.35 (-9.16%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
3.82
Day's Range
3.44 – 3.83
52-Week Range
1.70 – 7.07
Volume
1.1M
Avg Volume
1.9M
Share Statistics
Shares Outstanding
Employees
28
Exchange
XNAS
Listed
2020-11-06
Share count as of August 3, 2026

Opus Genetics, Inc. Common Stock (IRD) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Opus Genetics, Inc. Common Stock (IRD)
What is Opus Genetics, Inc. Common Stock's Market Cap?
Opus Genetics, Inc. Common Stock's Market Cap is $288.7M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · IRDAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
License and collaborations revenue
YoY growth-73.8%-50.6%-10.2%-20.4%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue2282.8%765.9%396.3%369.9%
Loss from operations
% of revenue-2182.8%-665.9%-296.3%-269.9%
Fair value change in instruments measured at fair value———
Financing costs
Other income, net
Loss before income taxes
Benefit (provision) for income taxes
Net loss
% of revenue-1072.6%-3038.2%-427.5%-566.9%
Basic (in dollars per share)
Diluted (in dollars per share)